5EC64886-2295-497A-BEE8-8AA17D8DADF1
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 38.86333771353482
- age_years
- 32
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.680
- INTERFERON_ALPHA_RESPONSE+0.659
- INTERFERON_GAMMA_RESPONSE+0.570
- TGF_BETA_SIGNALING+0.529
- NOTCH_SIGNALING+0.500
- INFLAMMATORY_RESPONSE+0.396
- WNT_BETA_CATENIN_SIGNALING+0.383
- MITOTIC_SPINDLE+0.369
- IL6_JAK_STAT3_SIGNALING+0.354
- MYC_TARGETS_V1+0.354
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.295
- SPERMATOGENESIS-0.230
- MYOGENESIS-0.222
- KRAS_SIGNALING_DN-0.215
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.142
- ANGIOGENESIS-0.137
- COAGULATION-0.121
- APICAL_JUNCTION-0.090
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.059
- BILE_ACID_METABOLISM-0.018
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AD62B8A4-6AB8-4C99-80F5-98A1C085027D | — | — | 0.909 |
| 2 | 90188F36-DEF6-4233-B724-4A25F2D52DAA | — | — | 0.909 |
| 3 | SRR934946 | — | — | 0.901 |
| 4 | 0108A1FA-9CBF-4CF6-8981-7FB39C39B335 | — | — | 0.894 |
| 5 | C81B24AB-2DBA-4624-A1D4-D4DCAC714506 | — | — | 0.889 |
| 6 | 928D2F99-A86B-47CA-A961-A8CAE7B44E78 | — | — | 0.883 |
| 7 | 6292335B-7CBB-45BE-AA2A-B39FFDA8768D | — | — | 0.883 |
| 8 | 8BC067E8-7BD6-41DA-8682-317236F42328 | — | — | 0.882 |
| 9 | 0F8BE394-BA6A-401C-87D0-9B3CF50FB0C8 | — | — | 0.878 |
| 10 | E6AA40DA-9AB7-478B-B46B-827F9AFE52D1 | — | — | 0.876 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.680 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.659 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.570 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.529 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.500 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.396 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.383 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.369 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.354 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.354 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.347 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.347 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.343 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.323 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.322 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.318 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.317 | Inavolisib | — uncovered |
| APOPTOSIS | 0.315 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.308 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.293 | Remibrutinib | — uncovered |